PC
CODX

Prairiewood Capital’s Co-Diagnostics CODX Stock Holding History

Prairiewood Capital’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,972
Closed -$149K – 74
2022
Q4 		$149K Hold
1,972
– – 0.11% 74
2022
Q3 		$190K Hold
1,972
– – 0.16% 72
2022
Q2 		$332K Hold
1,972
– – 0.26% 55
2022
Q1 		$366K Sell
1,972
-14
-0.7% -$2.9K 0.26% 54
2021
Q4 		$532K Buy
1,986
+7
+0.4% +$1.84K 0.42% 46
2021
Q3 		$578K Buy
+1,979
New +$578K 0.47% 44

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Prairiewood Capital's CODX Position: Q1 2023 in Review

Prairiewood Capital sold out of Co-Diagnostics (CODX) in Q1 2023, closing a stake of 1,972 shares — an estimated $149K sold.

Prairiewood Capital first reported a position in CODX in Q3 2021 and held it in 6 quarters. The position peaked at $578K in Q3 2021. 51 funds tracked by Wall St. Rank hold CODX as of Q1 2023.

  • Prairiewood Capital reported no remaining Co-Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Prairiewood Capital sold 1,972 Co-Diagnostics shares in Q1 2023, an estimated $149K.
  • Prairiewood Capital first reported a position in Co-Diagnostics in Q3 2021 and held it in 6 quarters.
  • Prairiewood Capital's Co-Diagnostics position peaked at $578K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2023.

Based on Prairiewood Capital's 13F filing for Q1 2023, filed 19 Apr 2023.